410 related articles for article (PubMed ID: 2150781)
21. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C
Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218
[TBL] [Abstract][Full Text] [Related]
22. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
23. Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis.
Duncan LM; Deeds J; Hunter J; Shao J; Holmgren LM; Woolf EA; Tepper RI; Shyjan AW
Cancer Res; 1998 Apr; 58(7):1515-20. PubMed ID: 9537257
[TBL] [Abstract][Full Text] [Related]
24. High levels of Met-72 antigen expression: correlation with metastatic activity of B16 melanoma tumor cell variants.
Kimura AK; Xiang JH
J Natl Cancer Inst; 1986 Jun; 76(6):1247-54. PubMed ID: 3486997
[TBL] [Abstract][Full Text] [Related]
25. Phorbol 12-myristate 13-acetate enhances nm23 gene expression in murine melanocytes but not in syngeneic B16-BL6 melanoma variants.
Huijzer JC; McFarland M; Niles RM; Meadows GG
J Cell Physiol; 1996 Mar; 166(3):487-94. PubMed ID: 8600152
[TBL] [Abstract][Full Text] [Related]
26. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity.
Melcher A; Todryk S; Bateman A; Chong H; Lemoine NR; Vile RG
Cancer Res; 1999 Jun; 59(12):2802-5. PubMed ID: 10383135
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of melanoma-associated antigen expression and ecotropic retrovirus production in B16BL6 melanoma cells transfected with major histocompatibility complex class I genes.
Li M; Muller J; Xu F; Hearing VJ; Gorelik E
Cancer Res; 1996 Oct; 56(19):4464-74. PubMed ID: 8813142
[TBL] [Abstract][Full Text] [Related]
28. Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth.
Gil-Ad I; Shtaif B; Levkovitz Y; Nordenberg J; Taler M; Korov I; Weizman A
Oncol Rep; 2006 Jan; 15(1):107-12. PubMed ID: 16328041
[TBL] [Abstract][Full Text] [Related]
29. Tumorigenicity and metastatic ability of MmB16 mouse melanoma cell line and its two Aleuria aurantia agglutinin resistant variants.
Duś D; Matuszyk J; Kuśnierczyk H; Strzadała L; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1992; 40(5-6):263-9. PubMed ID: 1340180
[TBL] [Abstract][Full Text] [Related]
30. Alpha-melanocyte-stimulating hormone blocks invasion of reconstituted basement membrane (Matrigel) by murine B16 melanoma cells.
Murata J; Ayukawa K; Ogasawara M; Fujii H; Saiki I
Invasion Metastasis; 1997; 17(2):82-93. PubMed ID: 9561027
[TBL] [Abstract][Full Text] [Related]
31. Selection of metastatic variants from heterogeneous tumor cell lines using the chicken chorioallantoic membrane and nude mouse.
Dexter DL; Lee ES; DeFusco DJ; Libbey NP; Spremulli EN; Calabresi P
Cancer Res; 1983 Apr; 43(4):1733-40. PubMed ID: 6831418
[TBL] [Abstract][Full Text] [Related]
32. [Xenogeneic melanoma-related antigen elicits anti-tumor immune response, companied by autoimmune injury].
Tan XH; Wan YH
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(23):1596-600. PubMed ID: 16185524
[TBL] [Abstract][Full Text] [Related]
33. Metastatic potential of murine B16 melanoma correlates with reduced surface heparan sulfate glycosaminoglycan.
Kure S; Yoshie O; Aso H
Jpn J Cancer Res; 1987 Nov; 78(11):1238-45. PubMed ID: 2961717
[TBL] [Abstract][Full Text] [Related]
34. Resistance to melanoma in mice immunized with semiallogeneic fibroblasts transfected with DNA from mouse melanoma cells.
de Zoeten EF; Carr-Brendel V; Cohen EP
J Immunol; 1998 Mar; 160(6):2915-22. PubMed ID: 9510195
[TBL] [Abstract][Full Text] [Related]
35. [Metastatic melanoma B16 of the C57Bl/6J mouse. Biological findings].
Voulot C; Aubert C; Rougé F; Douss T; Santini R
C R Seances Soc Biol Fil; 1985; 179(4):445-51. PubMed ID: 2938673
[TBL] [Abstract][Full Text] [Related]
36. Relationship between cellular procoagulant activity and metastatic capacity of B16 mouse melanoma variants.
Gilbert LC; Gordon SG
Cancer Res; 1983 Feb; 43(2):536-40. PubMed ID: 6848176
[TBL] [Abstract][Full Text] [Related]
37. Serologically detectable MHC and tumor-associated antigens on B16 melanoma variants and humoral immunity in mice bearing these tumors.
Baniyash M; Smorodinsky NI; Yaakubovicz M; Witz IP
J Immunol; 1982 Sep; 129(3):1318-23. PubMed ID: 7108209
[TBL] [Abstract][Full Text] [Related]
38. Persistence of immunogenic pulmonary metastases in the presence of protective anti-melanoma immunity.
Donawho CK; Pride MW; Kripke ML
Cancer Res; 2001 Jan; 61(1):215-21. PubMed ID: 11196164
[TBL] [Abstract][Full Text] [Related]
39. Identification of genes differentially expressed in B16 murine melanoma sublines with different metastatic potentials.
Ishiguro T; Nakajima M; Naito M; Muto T; Tsuruo T
Cancer Res; 1996 Feb; 56(4):875-9. PubMed ID: 8631027
[TBL] [Abstract][Full Text] [Related]
40. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
